Израел - Енглески - Ministry of Health

rafa laboratories ltd - buprenorphine - patches matrix - buprenorphine 20 mg - oripavine derivatives - treatment of moderate to severe opioid responsive chronic pain conditions which are not adequately responding to non-opioid analgesics.

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - theophylline - modified-release tablet - 175mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - theophylline - modified-release tablet - 250mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - theophylline - modified-release tablet - 175mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - theophylline - modified-release tablet - 250mg

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - labetalol hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - the emergency treatment of severe hypertension when prompt and urgent reduction of blood pressure is essential

Израел - Енглески - Ministry of Health

rafa laboratories ltd - buprenorphine - patches matrix - buprenorphine 15 mg - buprenorphine - treatment of moderate to severe opioid responsive chronic pain conditions which are not adequately responding to non-opioid analgesics.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml; sodium hydroxide - injection, solution - excipient ingredients: water for injections; sodium chloride; sulfuric acid - indications as at 30 september 2003:surgery : atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. the use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. after surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. cardiopulmonary resuscitation : atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. anticholinesterase poisoning : atropine juno is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, amanita muscaria mushrooms or other compounds with anticholinesterase activity. a cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

medtel pty ltd -

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

zeneca limited - halothane - inhalation vapour liquid - 99.99 %w/w